Summary
In a significant market movement during January 2025, Verdiva Bio was the subject of a vc funding. The transaction achieved a gross valuation of £333,829,804. Leading the round was Forbion, OrbiMed, RA Capital Management, Logos Capital, Lilly Asia Ventures, LYFE Capital, General Atlantic.
This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.
Lead Investor / Acquirer
Forbion
Lead Investor / Acquirer
OrbiMed
Lead Investor / Acquirer
RA Capital Management
Lead Investor / Acquirer
Logos Capital
Lead Investor / Acquirer
Lilly Asia Ventures
Lead Investor / Acquirer
LYFE Capital
Lead Investor / Acquirer
General Atlantic
Advising Broker
Undisclosed Firm
Related Deals in Healthcare & Biotech
Series A prioritisedOriginal Source
This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.
View on Tech.eu Funding ExplorerFunding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.
AI Insight Lenses
ProAI-generated analysis from four professional perspectives. Powered by PE Deals.
Sign in to unlock AI Lenses
Sign in